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Abstract
Background:  Chlamydiae are obligate intracellular bacteria, which are important human
pathogens. Genome sequences of C. trachomatis and C. pneumoniae have revealed the presence of
a Chlamydia specific gene family encoding polymorphic outer membrane proteins, Pmps. In C.
pneumoniae the family comprises twenty-one members, which are all transcribed. In the present
study, the expression, processing and localisation of the sixteen full-length Pmps in C. pneumoniae
strain CWL029 have been further investigated by two-dimensional gel electrophoresis and
immunofluorescence microscopy.
Results: Ten Pmps were identified in elementary bodies (EBs). Eight of these were investigated
with respect to time dependent expression and all were found to be up-regulated between 36 and
48 hours post infection. Antibodies against Pmp6, 8, 10, 11 and 21 reacted with chlamydiae when
infected cells were formalin fixed. Pmp6, Pmp20 and Pmp21 were found in cleaved forms, and the
cleavage sites of Pmp6 and Pmp21 were identified.
Conclusions: The Pmps are heavily up-regulated at the time of conversion of RB to EB, and at
least ten Pmps are present in EBs. Due to their reaction in formalin fixation it is likely that Pmp6,
8, 10, 11 and 21 are surface exposed. The identified cleavage sites of Pmp6 and Pmp21 are in
agreement with the theory that the Pmps are autotransporters.
Background
Chlamydiae are pathogenic gram-negative bacteria of
which C. pneumoniae  causes upper and lower respiratory
tract infections in humans [1]. Going through a develop-
mental cycle the chlamydiae alternate between infective
elementary bodies (EBs) and replicative reticulate bodies
(RBs) [2]. The bacteria are obligate and intracellular, re-
siding inside a specialized phagosome, named the
chlamydial inclusion. The duration of the developmental
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cycle for C. pneumoniae cultivated in cell culture is about
72 hours [3].
The C. pneumoniae CWL029 genome sequence revealed
the presence of a gene family, the pmp family, consisting
of 21 members [4] that were paralogous to the pmps found
in C. trachomatis [5] and C. psittaci [6–9]. The C. psittaci
Pmps have been analysed by two-dimensional electro-
phoresis in an earlier study [37]. The Pmps are two-do-
main proteins with similarity to autotransporter proteins
[4,10,11]. They are characterized by a high frequency of
the two sequences FxxN and GGAI in the N-terminal part
(twelve and seven repeats on average, respectively) [4],
and their C-terminal part shows the characteristics of a β-
barrel [10]. The GGAI motif and the prediction of a C-ter-
minal β-barrel suggest that the Pmps are autotransporters,
transporting an N-terminal passenger domain through a
pore formed by their C-terminal part [10,12]. Seventeen
C. pneumoniae Pmps contain a signal peptidase I cleavage
site directing transport over the inner membrane, and two
Pmps contain a signal peptidase II cleavage site suggesting
lipid modification [4].
The Mw of most Pmps in C. pneumoniae strain CWL029 is
predicted to be just below 100 kDa, but three are larger:
Pmp6 is 142 kDa, Pmp20 is 178 kDa and Pmp21 is 167
kDa and Pmp12 is only 56 kDa. Four genes (pmp3, 4, 5
and 17) contain a mutation resulting in premature stop.
In C. pneumoniae strain AR39 [13] and J138 [14]pmp6 con-
tains 393 less base pairs, and in strain J138 Pmp2 and
Pmp4 contain frame shift mutations [14].
Variation of membrane protein expression is thought to
provide protection against the immune system of the host
[15] and it has been suggested that the Pmps may provide
such a protection of chlamydiae. This was indicated by the
findings of Birkelund et al. [16] and Pedersen et al. [17]
who observed differential expression of Pmp10.
Transcripts have been detected from all Pmp genes in C.
trachomatis [18] as well as C. pneumoniae [19]. As part of a
large-scale proteome analysis [20], ten Pmps (Pmp2, 6, 7,
8, 10, 11, 13, 14, 20 and 21) or fragments of these were
identified by mass spectrometry (MS) in C. pneumoniae
CWL029 EBs. The positions of these in the 2-D protein
profile can be viewed at  [http://www.gram.au.dk]. In ad-
dition to these, Montigiani et al. [21] identified Pmp16 by
MS. Grimwood et al. [19] found Pmp2, 6, 7, 8, 9, 11, 13,
14, 15, 16, and 18 to be present in C. pneumoniae CWL029
EBs by immunoblotting (IMB) using antibodies raised
against synthetic 20-mer peptides. Pmp1, 19, 20 and 21
were not detected although full-length genes encode
these. Pmp6 migrated around 100 kDa although it theo-
retically should be 144 kDa.
The detection of Pmp6 forty kDa below the predicted val-
ue has been interpreted by Henderson and Lam [10] as an
indication that an N-terminal passenger domain is
cleaved off, which is frequently seen for autotransporters.
In strains AR39 and TW183, sharing the 393 base pair de-
letion, Pmp6 was detected at the resulting theoretical full-
length position of 130 kDa by Grimwood et al. [19].
In the study described in this paper, 2-D PAGE was used
to elucidate the expression pattern of the C. pneumoniae
Pmps in CWL029 at different times during the develop-
mental cycle. Pmp6, Pmp20 and Pmp21 were found to be
cleaved and the cleavage sites of Pmp6 and Pmp21 were
identified. IMF was used to determine whether Pmps
could be detected at the surface of the bacteria.
Results
The proteome study by Vandahl et al. [20] was not conclu-
sive on the absence of any Pmps. Hence, we performed 2-
D immnoblotting (IMB) to identify the 2-D PAGE posi-
tion of expressed Pmps not earlier mapped. Pmp3, 4, 5,
12 and 17 were omitted from the study because these are
truncated. Polyclonal antibodies (pAbs) were obtained by
immunization of rabbits with recombinant proteins pro-
duced in E. coli (table 1). Antigens were raised against the
N-terminal part of Pmp6, 7, 8, 10, 13, 14, 15, 16, 18, 19,
20 and 21 because antibodies raised against full length
Pmps showed cross-reactivity. The N-terminal part is the
most variable and has been detected at the surface for C.
psittaci Pmps [9]. All the obtained pAbs reacted in 1-D
IMB with the recombinant Pmps to which they were
raised (data not shown). The antigen for IMB was EB
lysate. Reacting spots (figure 1A) were identified by com-
parison to a reference gel upon autoradiography of the
blot (figure 1B) [22] or by MS analysis of spots excised
from corresponding gels.
The proteins detected by each antibody are listed in table
1 using bold for strong reaction and plain for weaker reac-
tion. PAb203-rPmp10 was mono-specific for Pmp10. The
antibodies against rPmp2, rPmp7, rPmp8 and rPmp11
recognized these Pmps (respectively), and additional
Pmps as listed in table 1. PAb221-rPmp6 recognized the
91 kDa spot that was earlier identified as originating from
Pmp6 [20] and in addition another Pmp6 spot at 60 kDa
marked X in figure 1A. PAb236-rPmp20 recognized a spot
located just above the 90 kDa Pmps, which was earlier
identified as originating from Pmp20 [20]. PAb237-
rPmp21 recognized the 91 kDa Pmp6 spot, Pmp13 and a
48 kDa Pmp21 fragment marked Y in figure 1C. The re-
sults with antibodies against rPmp1 and rPmp9 were in-
conclusive and MS identification of these Pmps could not
be obtained. Antibodies against rPmp16 and rPmp18
both reacted with Pmp8 and Pmp10 but no other pro-
teins. Antibodies against rPmp15 and rPmp19 did not re-BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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Figure 1
2-D immunoblotting of EB proteins Radiolabeled proteins from EBs purified 72 hpi were separated by 2-D PAGE and
electroblotted onto PVDF membranes. The membranes were reacted with polyclonal rabbit antibodies raised against recom-
binant Pmp. Bound antibodies were visualized by color reagents and membranes were afterwards exposed to X-ray films so
that reacting spots could be identified by comparison to an annotated gel. A: PVDF blot of EB proteins reacted with Pmp6-
pAb221, X shows a C-terminal fragment of Pmp6 recognized by Pmp6-pAb221; B: Autoradiography of A; C: PVDF blot of EB
proteins reacted with pAb237-rPmp21, Y shows an N-terminal fragment of Pmp21 recognized by pAb237-rPmp21.
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act with any EB proteins. We were thus not able to detect
Pmp 15, 16, 18 and 19 by IMB using EB lysates as antigen.
Identification of cleaved Pmps
The antibodies against the high molecular weight Pmps
(Pmp6, Pmp20 and Pmp21) recognized protein spots at
lower molecular weight than expected. PAb221-rPmp6
recognized a set of spots, X, at 60 kDa (figure 1A) in addi-
tion to the earlier identified 91 kDa fragment of Pmp6.
MS analysis of a tryptic digest of X revealed peptides from
the C-terminal part of Pmp6 (singly underlined peptides,
figure 2). In contrast, the mass spectra from the Pmp6 spot
at 91 kDa was found to contain peptides solely from the
N-terminal part of Pmp6 (doubly underlined peptides,
figure 2). To verify the identifications, gels were electrob-
lotted onto PVDF membranes and N-terminal amino acid
sequences of the proteins were assessed by Edman degra-
dation. The sequence obtained from X (xVPVVPVAP) con-
firmed that it was a C terminal fragment of Pmp6 as it
matched an internal sequence of Pmp6 (872SVPVVPVAP)
(figure 2). The sequence obtained from the N-terminal
fragment (xNTDLxSSD) matched a sequence of Pmp6
(24ANTDLSSSD) that confirmed cleavage at the signal
peptidase I cleavage site predicted by Signal-P [23,24] (fig-
ure 2). As seen in figure 2, these cleavage sites explain the
observed pI and Mw coordinates. Also in figure 2, a model
of Pmp6 is shown where the internal cleavage site is
mapped relative to the predicted domains.
PAb237-rPmp21 reacted with a novel spot pattern, Y, at
66 kDa (figure 1C). A tryptic digest of Y was found to con-
tain solely N-terminal peptides of Pmp21 by MS analysis
(amino acids 122–130, 181–202, 203–213, 251–268,
493–510, and 530–548). The earlier identified Pmp21
spot at 48 kDa [20] was found to contain solely C-termi-
nal peptides (amino acids 1205–1223, 1251–1273,
1279–1289, 1295–1311, 1312–1326, 1315–1326, 1400–
1417, 1447–1457, 1464–1483, 1465–1483, 1484–1494,
1502–1521, 1504–1521, 1525–1540, 1594–1606). No
reaction was observed with the latter spot (figure 1C) ex-
plained by the fact that pAb237-rPmp21 was raised
against a recombinant protein covering only the N-termi-
nal part of Pmp21, up to amino acid 1129 (table 1). Ed-
man degradation of the 48 kDa spot revealed a sequence
matching an internal sequence of Pmp21
(1185SSPTPNKDKA) thereby identifying the cleavage site.
Table 1: Overview of Pmps, antibodies and immunoblot reactions
pAb Pmp Cl. Fam. L aa cloned MS G M IMB MeOH Form.
204 1 I G I 923 26–923 --I 1 ? 2 6 78 10 13 14 20 21 X -
207 2 I G I 842 20–842 XSM 2 6 8 10 X-
-3 * IG I
-4 * IG I
-5 * IG I
221 6 II G I 1408 18–905 N+C S M 6 8 10X XX
220 7 II G I 937 25–545 X S 2 6 7 8 10 11 13 X -
201 8 II G I 931 21–931 X S M 8 10 XX
208 9 II G I 929 27–929 -SI 2   6 7 8 9? 10 11 13 14 
20
Xu
203 10 II G II 929 20–929 X-M 10 XX
195 11 II G II 929 1–929 XWM 6 11 XX
- 12# II - I
222 13 II G I 974 20–542 X S M not performed X-
228 14 II H I 979 25–492 X S M not performed X-
229 15 III EF I 939 18–478 - W I - - -
230 16 III EF N 935 1–472 - S M 8 10 - -
-1 7 * III EF I
231 18 III EF N 893 1–566 - P 8 10 - -
234 19 IV A I 948 22–501 - - - - -
236 20 IV BC I 1724 22–1272 X - M 20 13 - -
237 21 D I 1610 52–1129 N+C - M 6 13Y XX
pAb: Antibody number; Pmp: Pmp number: *, genes containing a premature stop; #, naturally short gene; shading indicates either * or #. Cl.: Clus-
ter in the C. pneumoniae genome.L: Predicted leader sequences: I, signal peptidase I cleavage site; II, signal peptidase II cleavage site; -, no predicted 
cleavage site. Fam.: Closest related C. trachomatis Pmp. aa: Amino acids in full-length Pmp. cloned: First and last amino acid in the recombinant 
protein. MS: Mass spectrometry identification by: X, peptides dispersed along the entire sequence; N, peptides localized to the N-terminal part; C, 
peptides localized to the C-terminal part; -, not identified by MS. G: Detection in 1D IMB by Grimwood et al.: S, strong reaction; W, weak reaction; 
P, possible reaction; -, no reaction. M: Detection by Montigiani et al. [24]: M, MS and immunoblot identification; I, immunoblot detection alone. 
IMB: Immunoblotting results: bold numbers indicate strong reaction; X is a C-terminal fragment of Pmp6; Y is an N-terminal fragment of Pmp21; 
results marked ? were inconclusive. MeOH: MeOH fixation IMF at 72 hpi: X, reaction; -, no reaction. Form.: Formalin fixation IMF at 72 hpi: X 
specific reaction; u, unspecific reaction; -, no reaction.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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Figure 2
Pmp6 fragments Peptides identified from the acidic protein spot by MS are doubly underlined. Peptides identified from the
basic spot are singly underlined. Amino acids from N-terminal sequences obtained by Edman degradation of the fragments are
shown in bold. GGAI/L repeats are boxed. Notice that all repeats are located N-terminally of the cleavage site. Theoretical pI
and Mw values of fragments were calculated by the Compute pI/Mw tool  [http://www.expasy.ch/tools/pi_tool.html]. A sche-
matic drawing of the predicted domains is shown at the bottom, the pair of scissors representing the internal cleavage site.
0001 MKYSLPWLLT SSALVFSLHP LMAANTDLSS SDNYENGSSG SAAFTAKETS DASGTTYTLT
0061 SDVSITNVSA ITPADKSCFT NTGGALSFVG ADHSLVLQTI ALTHDGAAIN NTNTALSFSG
0121 FSSLLIDSAP ATGTSGGKGA ICVTNTEGGT ATFTDNASVT LQKNTSEKDG AAVSAYSIDL
0181 AKTTTAALLD QNTSTKNGGA LCSTANTTVQ GNSGTVTFSS NTATDKGGGI YSKEKDSTLD
0241 ANTGVVTFKS NTAKTGGAWS SDDNLALTGN TQVLFQENKT TGSAAQANNP EGCGGAICCY
0301 LATATDKTGL AISQNQEMSF TSNTTTANGG AIYATKCTLD GNTTLTFDQN TATAGCGGAI
0361 YTETEDFSLK GSTGTVTFST NTAKTGGALY SKGNSSLTGN TNLLFSGNKA TGPSNSSANQ
0421 EGCGGAILAF IDSGSVSDKT GLSIANNQEV SLTSNAATVS GGAIYATKCT LTGNGSLTFD
0481 GNTAGTSGGA IYTETEDFTL TGSTGTVTFS TNTAKTGGAL YSKGNNSLSG NTNLLFSGNK
0541 ATGPSNSSAN QEGCGGAILS FLESASVSTK KGLWIEDNEN VSLSGNTATV SGGAIYATKC
0601 ALHGNTTLTF DGNTAETAGG AIYTETEDFT LTGSTGTVTF STNTAKTAGA LHTKGNTSFT
0661 KNKALVFSGN SATATATTTT DQEGCGGAIL CNISESDIAT KSLTLTENES LSFINNTAKR
0721 SGGGIYAPKC VISGSESINF DGNTAETSGG AIYSKNLSIT ANGPVSFTNN SGGKGGAIYI
0781 ADSGELSLEA IDGDITFSGN RATEGTSTPN SIHLGAGAKI TKLAAAPGHT IYFYDPITME
0841 APASGGTIEE LVINPVVKAI VPPPQPKNGP IASVPVVPVA PANPNTGTIV FSSGKLPSQD
0901 ASIPANTTTI LNQKINLAGG NVVLKEGATL QVYSFTQQPD STVFMDAGTT LETTTTNNTD
0961 GSIDLKNLSV NLDALDGKRM ITIAVNSTSG GLKISGDLKF HNNEGSFYDN PGLKANLNLP
1021 FLDLSSTSGT VNLDDFNPIP SSMAAPDYGY QGSWTLVPKV GAGGKVTLVA EWQALGYTPK
1081 PELRATLVPN SLWNAYVNIH SIQQEIATAM SDAPSHPGIW IGGIGNAFHQ DKQKENAGFR
1141 LISRGYIVGG SMTTPQEYTF AVAFSQLFGK SKDYVVSDIK SQVYAGSLCA QSSYVIPLHS
1201 SLRRHVLSKV LPELPGETPL VLHGQVSYGR NHHNMTTKLA NNTQGKSDWD SHSFAVEVGG
1261 SLPVDLNYRY LTSYSPYVKL QVVSVNQKGF QEVAADPRIF DASHLVNVSI PMGLTFKHES
1321 AKPPSALLLT LGYAVDAYRD HPHCLTSLTN GTSWSTFATN LSRQAFFAEA SGHLKLLHGL
1381 DCFASGSCEL RSSSRSYNAN CGTRYSF
Theoretical values Observed values
Fragment kDa pI Fragment kDa pI
Full length 142.3 5.28 Full length not observed
N-terminal 84.8 4.64 Acidic spot 91.3 4.63
C-terminal 57.5 6.75 Basic spot 60.0 6.67
C
N
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Cleavage at this site results in a fragment of a theoretical
Mw of 51 kDa, which is in good agreement with the ob-
served Mw of 48 kDa. For the protein spot at 66 kDa con-
taining the N-terminal peptides, cleavage at the signal
peptidase cleavage site predicted by Signal-P was con-
firmed at the amino acid 30 (30AHSLHSSELD). The theo-
retical molecular weight of a fragment starting at this
position and ending at the cleavage site at amino acid
1185 is 116 kDa. As no peptides were identified at the C-
terminal side of amino acid 548 in the N-terminal frag-
ment, further cleavage or degradation from the C-terminal
end will be a likely explanation of the discrepancy be-
tween expected and observed values.
Pmp20 was identified just above the 90 kDa Pmps, but as
no molecular weight markers were present above 90 kDa,
the exact molecular weight of the protein cannot be de-
duced. However, it is found much lower than the expected
178 kDa and the earlier obtained MS identification of this
protein spot was based on peptides located in the C-termi-
nal part of Pmp20 (residues 1057–1069, 1387–1400,
1421–1432, 1506–1527, 1557–1571, 1587–1597, and
1644–1654) indicating that also Pmp20 is cleaved.
2-D PAGE analysis of time dependent expression
The time of expression of the Pmps identified in the 2-D
protein profile was investigated by pulse labeling with
[35S]methionine for two-hour-periods followed by 2-D
PAGE and autoradiography. Samples were labeled at 12,
24, 36, 42 and 48 hours post infection (hpi). The earliest
time for detection of Pmps was 24 hpi, at which time the
highest abundant Pmps in the gels (Pmp8 and Pmp10)
were only barely visible (figure 3A). The amount of Pmps
expressed in a two-hour labeling period increased during
the developmental cycle as illustrated for Pmp8 and
Pmp10 in figure 3A,3B,3C,3D. In figure 4 the volumes of
Pmp spots (Pmp2, 7, 8, 10, 11, 13, 14 and the C-terminal
part of Pmp6) are plotted as percentages of the total spot
volumes of the gels at 24, 36 and 48 hpi. The remaining
identified Pmps were omitted from this analysis since
they could not be confidently quantified due to overlap-
ping spots. Spot volumes were calculated as density inte-
grated over Gaussian area of spots visualized by
autoradiography and detected by use of the Melanie II
software. The volume of each spot was divided by the
number of methionines of the protein. The corrected vol-
ume percentages are arbitrary, as the total spot volumes of
the gels could not be corrected for methionine content of
every protein present in the gel. However, the numbers do
reflect the mutual proportion of the measured proteins
and the time dependent change in their contribution to
the total protein synthesis. Over time, the expression of all
the Pmps in figure 4 increased from below 0.05 units at 24
hpi to between 0.15 and 1.35 units at 48 hpi. The most
pronounced increase was from 36 to 48 hpi. Pmp10 was
found to be expressed at the highest rate (1.5 units at 48
hpi) followed by Pmp8 (0.6 units at 48 hpi). It must be
noted that the apparent level of expression is influenced
by the properties of the proteins with respect to separation
by 2-D PAGE. However, the Pmps must be expected to ex-
hibit comparable behaviour.
A parallel analysis of the expression of MOMP and DnaK
was performed for comparison to the Pmps (figure 4).
MOMP is expressed during the growth fase of Chlamydiae
[25]. DnaK is an early protein [26] and has been suggested
to be RB specific and hence to show decreased expression
late in the developmental cycle [27]. The expression of
MOMP was found to increase at the same rate from 24 to
36 hpi as from 36 to 48 hpi (figure 4). The expression of
DnaK was similar to that of MOMP at 24 hpi, but showed
no increase from 24 to 36 hpi and decreased from 36 to
48 hpi (figure 4).
It can be concluded that all Pmps investigated with respect
to time dependent regulation (Pmp2, 6, 7, 8, 10, 11, 13,
14) were found to be strongly up-regulated between 36
and 48 hpi, coinciding with the conversion of RB to EB.
This is in agreement with what has been reported for C.
trachomatis  and  C. psittaci POMPS [28,29]. At 48 hpi
Pmp8 and Pmp10 were several fold higher expressed than
any other Pmp.
Figure 3
Visualization of Pmp8 and Pmp10 by two-hour labe-
ling and 2-D PAGE Sections from autoradiographs of 2-D
PAGE separated proteins from C. pneumoniae infected cells
labeled with [35S]methionine by two-hour cultivation in a
[35S]methionine medium added cycloheximide.
Pmp8 Pmp8
Pmp8 Pmp8
Pmp10 Pmp10
Pmp10 Pmp10
24 hpi 36 hpi
42 hpi 48 hpi
AB
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Immunofluorescence microscopy
In order to investigate whether the Pmps absent from EBs
could be detected during growth in cell culture, the anti-
bodies against these Pmps were used in IMF on C. pneu-
moniae infected HEp-2 cells. Cells cultivated on coverslips
were infected and fixed in methanol at 72 hpi. The inves-
tigated antibodies were visualized with a FITCH conjugat-
ed secondary antibody. The antibodies against rPmp15,
16, 18 and 19, which did not react in IMB, did not react in
IMF either (table 1). Furthermore, Pab236-rPmp20 was
found not to react in IMF (table 1) although Pmp20 was
identified in EB gels by IMB and MS. Examples are shown
in figure 5.
All Pmp antibodies were used in IMF of infected cells that
were formalin fixed at 72 hpi. Formalin cross-linking of
outer membrane proteins prevents antibodies from pene-
trating the bacteria so that only proteins in the outer
membrane are accessible. MAb18.1-DnaK was included as
a control of the impermeability as described earlier [30].
As the DnaK epitope recognized by MAb18.1 is formalin
insensitive [30], the lack of reaction of MAb18.1 (figure 5,
row 1) must be due to the prevention of reaction of inte-
rior proteins by the fixation.
The pAbs raised against recombinant Pmp1, 2, 7, 13, 14,
15, 16, 19 and 20 did not react after formalin fixation.
Due to the described cross-reaction of the Pmp antibod-
ies, the reacting antibodies were absorbed with recom-
binant proteins. The Pmp antibodies were absorbed with
rPmps corresponding to the Pmps to which they cross-re-
acted in IMB and with the rPmps to which they were
raised, respectively. The reaction of pAb208-rPmp9 could
be prevented by addition of any of the Pmps 6, 8, 10, 11
or 21 (table 2), and hence it must be considered non-spe-
cific. The pAbs raised against rPmp6, 8, 11 and 21 were
found to react specifically in formalin fixation (table 2), as
their reaction was prevented by the recombinant Pmp that
they were raised agains, but not by the ones to which they
cross reacted in IMB. Pmp8 is shown as an example in fig-
ure 5 (6). Pab203-rPmp10 was not investigated by com-
petition IMF as it was shown to be mono-specific for
Pmp10 by IMB.
Figure 4
Time dependent expression of Pmps Histogram showing the contribution of selected Pmps to the total amount of pro-
tein synthesized in a two-hour labeling period. Chlamydia proteins were selectively labeled with [35S]methionine under the
addition of cycloheximide to stop host cell protein synthesis, separated by 2-D PAGE and visualized by autoradiography.
Infected cells were labeled at 24, 36 and 48 hours post infection. Spots were detected by using the MelanieII software. Spot
volumes were calculated as density integrated over Gaussian area, and the percentage of total spot volume in each gel was cal-
culated. The percentages were corrected for the methionine content of each protein. The corrected spot volume percentages
are given in arbitrary units at the Y-axis. Only Pmps located in the gel at positions where no overlapping protein spots hindered
quantification are depicted. MOMP and DnaK are included as controls.
0
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1,5
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2,5
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3,5
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4,5
Pmp2 Pmp7 Pmp8 Pmp10 Pmp11 Pmp13 Pmp14 Pmp6C MOMP DnaK
24 hpi 36 hpi 48 hpiBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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Pmp10 [30,17] and Pmp11[30] have earlier been shown
to be surface exposed and the results indicate that this is
also the case for Pmp6, 8 and 21. Other Pmps may also be
at the surface, but in that case the epitopes recognized by
our antibodies have been destroyed by the fixation or in
some way masked.
PAb116-rMOMP did not react after formalin fixation (fig-
ure 5, row 2), which is in agreement with earlier reports
on the lack of surface exposed linear epitopes of C. pneu-
moniae MOMP [31]. Pab110-rOmp2 did react (figure 5,
row 3) indicating the presence of surface exposed epitopes
of Omp2 in C. pneumoniae in opposition to C. trachomatis
where Omp2 is probably located at the inner surface of
the outer membrane complex [32,33].
Discussion
In the present study, cleavage sites of Pmp6 and Pmp21
have been identified, and it is suggested that also Pmp20
is cleaved. Cleavage of the these Pmps explain why they
are found at different molecular weight in different stud-
ies. Grimwood et al. [19] detected the N-terminal frag-
ment of Pmp6 at 90 kDa that was also identified by
Vandahl et al. [20], whereas Montigiani et al. [21] found
the lower molecular weight C-terminal fragment of Pmp6.
Only a C-terminal fragment of Pmp21 has been described
previously [20,21].
There is no similarity in amino acid sequence between the
cleavage sites in Pmp6 and Pmp21, but both sites are lo-
cated between the C-terminal predicted β-barrel [10] and
the N-terminal predicted parallel β-helix fold [34]. This
position is in agreement with the theory that the Pmps
may be autotransporters; as such often cleave off their N-
terminal part [10]. However, if the N-terminal part is lib-
erated it would not be detected in IMB using proteins
from purified EBs as antigens, and as the N-terminal frag-
ment is detected in EB gels for Pmp6 and Pmp21 it must
be concluded that it remains bound to the EB.
Pab236-rPmp20 was raised against a fragment of Pmp20
covering the N-terminal part and some of the C-terminal
fragment, but only the C-terminal part could be detected
in IMB (data not shown), suggesting that the N-terminal
part may be liberated. Pab236-rPmp20 did not react in
IMF. It was raised against unfolded recombinant protein
and may not recognize the correctly folded protein, espe-
cially not if the N-terminal part is liberated or degraded.
The fragments of Pmp6, Pmp20 and Pmp21 were detected
after a labeling period of two hours, and no increase in the
amount of cleavage products was observed after a chase
period of six hours (data not shown). This suggests that
the cleavage occurs rapidly after synthesis. We consider it
unlikely that the cleavage should be an artificial phenom-
enon as the infected cells were harvested in a lysis solution
containing 7 M urea, 2 M thiourea and reducing agents,
and as the results were highly reproducible. The lack of de-
tection of full-length products of the high molecular
weight Pmps may be caused by low resolution in 2-D
PAGE of such proteins, but full-length products of these
were also absent in 1-D IMB by Grimwood et al. [19]. In-
terestingly, Grimwood et al. [24] detected Pmp6 from
strains TW183 and AR39 at a Mw of 130 kDa, which is the
theoretical Mw of Pmp6 in these strains, due to a deletion
of the bases encoding amino acids 429 to 559, which does
not include the cleavage site.
In the present study we did not detect any of the Pmps15-
18, originating from cluster III. Pmp16 and Pmp18 are the
only Pmps lacking a leader sequence. Pmp17 is truncated
Figure 5
Immunofluorescence microscopy of C. pneumoniae
infected HEp-2 cells Immunofluorescence microscopy pic-
tures of infected HEp-2 cells fixed in methanol or 3.7% for-
maldehyde at 72 hours post infection (hpi). Bound antibody
was detected with a FITCH conjugated secondary antibody.
Fixed cells reacted with 1: Monoclonal antibody recognizing
DnaK (MAb18.1), 2: pAb116-rMOMP, 3: pAb110-rOmp2, 4:
pAb237-rPmp21,  5:  pAb234-rPmp19.  6:  Competition IMF.
Reaction with pAb201-rPmp8 in the presence of: rPmp8:
rPmp8, to which the antibody was raised, rPmp10: rPmp10,
to which the antibody cross reacted in IMB, control: no
recombinant proteins. As rPmp8 prevents reaction of
pAb201-rPmp8 whereas rPmp10 does not affect the reac-
tion, we conclude that the observed reaction is specific for
Pmp8.
MeOH 72hpi Formalin 72hpi
1
2
3
4
5
Formalin 72 hpi
rPmp8
rPmp10
6 PAb201-rPmp8
controlBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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and was thus not investigated. Montigiani et al. [21] have
reported identification of Pmp16 in C. pneumoniae from a
clinical isolate, but Grimwood et al. [19] found that both
Pmp16 and Pmp18 were unstable in CWL029, which may
explain that these Pmps were not observed in our study.
However, it could also be speculated whether differences
have been introduced through laboratory passages. We
observe expression of Pmp10 in strain CWL029 whereas it
was not detected in strain CWL029 by Grimwood et al.
[19] due to a frame shift mutation. Grimwood et al. [19]
have described differences in the expression of Pmp1 and
Pmp3 between strains CWL029 and TW183 as deter-
mined by immunoblotting, meaning that at least some
Pmps are differentially expressed between strains.
Pmp6, Pmp8, Pmp10, Pmp11 and Pmp21 were detected
at the surface of the bacteria by formalin fixation IMF.
Apart from Pmp21, all the Pmps detected at the surface
show greatest similarity to PmpG [4], a constituent of the
outer membrane of C. trachomatis L2 [35,28]. An explana-
tion of the expansion of the number of C. pneumoniae
Pmps similar to PmpG could be that C. pneumoniae varies
its surface to escape the immune defence of the host by
changing the expression of Pmps. However, if Pmp ex-
pression is changed in order to vary the surface, this is
most likely a consequence of the surface localization of
Pmps rather than the very reason for the existence of
Pmps.
The most highly expressed among all the investigated
Pmps at all points in time is Pmp10, which is known to
contain surface exposed epitopes [30]. Pmp10 is differen-
tially expressed in infected cell culture [17] and mice [16].
Pmp10 still being the most highly expressed Pmp suggests
that it carries out an important function. This function
would presumably have to be supplemented in bacteria
not expressing Pmp10. Pmp10 contains a predicted signal
peptidase II cleavage site directing lipid modification and
pmp11, which is located next to pmp10 (but in the oppo-
site direction), encodes the only other predicted lipid
modified Pmp. If the function of Pmp10 depends on lipid
modification, and this function is needed in bacteria lack-
ing Pmp10, Pmp11 would be the obvious alternative.
The finding that all Pmps are heavily upregulated at the
time of conversion of RBs into EBs indicates that the func-
tion of these is structural but they may also be needed
with respect to attachment or entry of EBs. An N-terminal
triangular beta-layer motif could provide the bacteria with
a shielding lattice and ensure proper spacing to a host cell
or an epitope exposed to the complement system. If the li-
pid modifications of Pmp10 and Pmp11 are used as an-
chors inserted into the host cell membrane, subsequent
action of other entry molecules would probably depend
on proper spacing. However, all theories on functions of
the Pmps remain very speculative.
Conclusions
The Pmps investigated with respect to time dependent reg-
ulation (Pmp2, Pmp6, Pmp7, Pmp8, Pmp10, Pmp11,
Pmp13, and Pmp14) were found to be up-regulated late
in the developmental cycle. Due to their reaction in for-
malin fixation we propose that Pmp6, Pmp8, Pmp10,
Pmp11, and Pmp21 are surface exposed. Pmp6, Pmp20
and Pmp21 were found in cleaved forms and the identi-
fied cleavage sites of Pmp6 and Pmp21 are in agreement
with the theory that the Pmps are autotransporters.
Methods
Organisms and cultivation
C. pneumoniae CWL029 (also known as VR1310) (ATTC)
was cultivated in semi confluent monolayers of Hep-2
cells (ATCC) as described [20]. Elementary bodies were
purified 72 hpi essentially as described [30] with the ex-
ception that Visipaque replaced Urografin for gradient
making.
PCR and cloning
PCR enzymes were Expand™ High Fidelity (Roche) and re-
action conditions were as recommended by the manufac-
Table 2: Competition immunofluorescence
none rPmp6 rPmp11 rPmp8 rPmp9 rPmp21 rPmp7 rPmp10
pAb221-rPmp6 +++ 0 +++
pAb195-rPmp11 +++ + 0
pAb201-rPmp8 +++ 0 +++
pAb208-rPmp9 + + 0000 0
pAb237-rPmp21 +++ +++ 0
 The results of competition IMF in which the recombinant Pmp listed in the top row was added to an IMF reaction using the polyclonal antibodies 
listed in the first column. The reactions were carried out only for the shaded table cells: 0, no reaction; +, weak reaction; ++, moderate reaction; 
+++, strong reaction.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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turer. As the Ligation-Independent Cloning (LIC) kit
(Novagen) was used for cloning of PCR products, all
primers (DNA Technology) were designed with LIC spe-
cific 5'-sequences: Forward primer: 5' GAC GAC GAC AAG
AT pmp-sequence 3'. Reverse primer: 5' GAG GAG AAG
CCC GGT pmp-sequence 3'. Primers for amplification of
pmp genes were placed as listed in table 1 and the sequenc-
es were obtained from GeneBank (AE001363). In those
cases where only the N-terminal of the Pmp gene was
cloned a stop codon was introduced. The pET 30Ek LIC
vector (Novagen) was used for cloning and expression of
recombinant protein according to the protocol provided
by the manufacturer. Cloning was performed in E. coli No-
vaBlue.
Protein expression and purification
Plasmid DNA was prepared from NovaBlue cells by the al-
kaline lysis method and used for transformation of E. coli
BL21(DE3) by eletroporation. Clones were tested for cor-
rect insert sequence by PCR with vector specific primers.
The PCR product was used for sequence reactions using
the Terminator Ready Reaction Mix (Perkin Elmer), and
sequencing performed on an ABI PRISMTM 377 DNA Se-
quencer (Perkin Elmer). IPTG (1 mM) induction of ex-
pression of His-tagged fusion proteins was performed for
two hours at 37°C when A600 reached 0.4. Recombinant
protein was purified from pelleted cells using HiTrap Ni2+
columns (Amersham Pharmacia). The purity of the re-
combinant proteins was tested by SDS PAGE and the pro-
tein concentration measured by use of the Bradford
Protein Assay (BioRad).
Production of antibodies
New Zealand White rabbits were immunized: i) intramus-
cularly on days 1, 8 and 15 using 10 µg of protein in PBS
and 50% Freunds incomplete adjuvant; ii) intravenously
on days 29, 36 and 43 using 10 µg of protein in PBS. The
rabbits were bled on day 60.
Labeling
Pulse labeling of infected cell cultures was performed by
using 100 µCi/mL radioactive methionine (Amersham
Pharmacia) in a methionine-free RPMI 1640 medium as
described previously [20]. 40 µg/mL cycloheximide was
added to inhibit host cell protein synthesis during labe-
ling. Cell cultures were labeled for two-hour-periods at 6,
12, 24, 26, 42, 48 and 54 hpi and harvested immediately
after labeling by scraping off in lysis solution (7 M urea, 2
M thiourea, 4% w/v CHAPS, 40 mM Tris base, 65 mM
DTE and 2% v/v Pharmalyte 3–10 (Amersham Pharma-
cia)). Before purification of EB the same labeling periods
were used to ensure incorporation of radioactivity into
proteins synthesized at all times during the developmen-
tal cycle.
Electrophoresis
One-dimensional SDS gels were run as described [30].
The protocol for two-dimensional gel electrophoresis was
as described [20]. First dimension was carried out using
non-linear Immobiline Drystrips pH 3–10 (Amersham
Pharmacia). Proteins were focused in the strips using an
IPGphor (Amersham Pharmacia) applying a voltage of 20
V for rehydration of strips and 120 kVh for focusing. For
second dimension 9–16% T gradient polyacrylamide SDS
gels were used. Comparative gels were loaded with
300.000 cpm as determined by TCA precipitation and
scintillation counting. Gels for N-terminal sequencing
were loaded with 600 µg protein from purified unlabeled
EB. Gels for MS identification were loaded with 3.000.000
cpm and a total of 600 µg protein – all from purified EB.
Gels for IMB were loaded with 75 µg protein from purified
unlabeled EB and 300.000 cpm labeled EB protein. Pro-
tein spots in gels were visualized by autoradiography as
described [20]. Comparative gels were treated with Ampli-
fy (Amersham Pharmacia) before exposure to BioMax MR
X-ray films (Kodak).
Immunoblotting
Two-dimensional gels were washed for five min. in dou-
ble-distilled water and soaked for 30 min. in transfer buff-
er. PVDF membranes (Immobilon-P, pore size 0.45 µm,
Millipore) were soaked for one min. in methanol and
then for 30 min. in transfer buffer. The transfer buffer con-
tained: 50 mM Tris, 50 mM boric acid, 0.02% SDS and
10% methanol. The transfer was performed at 90 V and
10°C for four hours. Membranes were blocked in a buffer
containing 20 mM Tris, 150 mM NaCl, and 3% gelatine,
pH 7.5, washed in washing buffer (20 mM Tris, 500 mM
NaCl, 0.05% tween-20) and incubated with polyclonal
antibodies (pAbs) diluted 1/300 in antibody buffer
(washing buffer added 0.2% gelatine) for one hour at 37°.
After three washing steps membranes were incubated with
secondary antibody (goat-anti-rabbit-IgG-AP-conjugate,
BioRad) diluted 1/2000 for another hour at 37°C. After
washing the blots, bound antibody was visualized with
270 µL NBT (50 mg/mL in 70% DMF) and 270 µL BCIP
(25 mg/mL in 100% DMF) in 45 mL buffer containing
100 mM NaCl, 5 mM MgCl and 100 mM Tris-HCl at pH
9.5. As a fraction of the EB proteins was radiolabeled, re-
acting spots could be identified by comparison to a refer-
ence gel [20] upon autoradiography of the PVDF
membrane [22].
Mass spectrometry
Protein spots excised from preparative gels were identified
by MALDI TOF mass spectrometry as described [20].
N-terminal sequencing
Protein spots excised and pooled from eight Coomassie
Brilliant Blue stained PVDF membranes each loaded withBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/36
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600 µg of protein from purified EB were analyzed using an
Applied Biosystems 404 protein sequencer (Perkin Elm-
er).
Immunofluorescence microscopy
IMF was performed as described [36] analyzing infected
cells fixed in methanol or formalin at 72 hpi. Formalin
fixed cells were permeabilized with 0.2% Triton X-100 for
10 minutes at room temperature. Bound primary anti-
body was visualized with a secondary FITCH conjugated
antibody (DAKO), which was absorbed to prevent cross-
reaction.
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